Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Side effects of vaccination that affected participants’ children. حسب Sara Saleh (6733619)

الموضوعات:

Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. حسب Francesca Catto (21253435)

"…Additionally, the plots on the right side display the average plaque count across the cohorts. …"

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Average stability values (mean ± standard deviation) and statistical results. حسب Hyung Suk Yang (20442438)

الموضوعات:

Individual stability values for different gait events under various conditions. حسب Hyung Suk Yang (20442438)

الموضوعات:

Dynamic stability based on the Feasible Stability Region (FSR). حسب Hyung Suk Yang (20442438)

الموضوعات:

Most significant muscle activation values. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Significant repeated measurements sEMG outcomes. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Significant single measurement sEMG outcomes. حسب María Benito-de-Pedro (22057468)

الموضوعات:

Inotodiol decreases clone formation in HCC cells. حسب Yushuang Xing (20636685)

"…Chemicals and chemotherapeutic agents have been experiencing problems such as side effects and drug resistance in the treatment of HCC, which cannot meet the needs of clinical treatment. …"

Inotodiol decreases clone formation in HCC cells. حسب Yushuang Xing (20636685)

Side effect. حسب My Tra Thi Nguyen (22120541)

"…QoL also significantly improved, with CU-Q2oL scores dropping from 44.9 at baseline to 25.3 at week 8. …"

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

الموضوعات:

Participant demographic and clinical characteristics. حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... حسب Claire M. Douglas (21238238)

الموضوعات:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... حسب Claire M. Douglas (21238238)

الموضوعات: